Search clinical trials for: SCH 58235

Total 2325 results

Organon and Co

Completed

Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)

Primary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)

Atherosclerosis | Hypercholesterolemia | Coronary Heart Disease
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia

Heart Diseases | Metabolism, Inborn Errors

United States
Organon and Co
Merck Frosst Canada Ltd.

Terminated

Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)

Atherosclerosis | Hypercholesterolemia
National Heart, Lung, and Blood Institute (NHLBI)

Completed

SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia

Lipoidosis

United States
Organon and Co

Completed

Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)

Hypercholesterolemia
Organon and Co

Completed

Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)

Hypercholesterolemia | Coronary Heart Disease
Organon and Co

Completed

Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)

Hypercholesterolemia | Coronary Heart Disease
Organon and Co

Completed

Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)

Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)

Primary Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578) (ENHANCE)

Atherosclerosis | Hypercholesterolemia | Hyperlipoproteinemia Type II
Organon and Co

Completed

Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)

Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)

Atherosclerosis | Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)

Atherosclerosis | Hypercholesterolemia
Organon and Co

Completed

Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)

Hypercholesterolemia
Organon and Co

Completed

A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)

Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Terminated

Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)

Atherosclerosis | Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)

Hypercholesterolemia
Organon and Co

Completed

Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)

Hypercholesterolemia
Organon and Co

Completed

A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)

Hypercholesterolemia
Organon and Co

Completed

Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)

Hypercholesterolemia
Organon and Co

Completed

Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)

Dyslipidemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)

Coronary Artery Disease | Atherosclerosis | Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)

Atherosclerosis | Hypercholesterolaemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)

Atherosclerosis | Hypercholesterolemia
Organon and Co

Completed

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)

Atherosclerosis | Hypercholesterolemia
University Hospitals Cleveland Medical Center
University of Pittsburgh; The Cleveland Clinic; Duke University; Case Western Reserve... and other collaborators

Recruiting

Patient-Centered Outcomes in the Surgical Treatment of Uterovaginal Prolapse (PREMIER)

Uterine Prolapse

United States
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)

Bladder Neoplasms
Merck Sharp & Dohme LLC

Completed

Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Cantonal Hospital of St. Gallen

Terminated

ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT (ThoHSpEkt)

Bronchial Neoplasms | Solitary Pulmonary Nodule

Switzerland
Organon and Co

Completed

Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)

Primary Hypercholesterolemia
ALK-Abelló A/S

Completed

A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)

Allergy
Vertex Pharmaceuticals Incorporated
ViroChem Pharma

Completed

A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.

Hepatitis C, Chronic

Canada
Organon and Co
Merck Sharp & Dohme LLC

Terminated

Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)

Coronary Artery Disease | Atherosclerosis | Hypercholesterolemia
National Cancer Institute (NCI)

Active, not recruiting

Dinaciclib in Treating Patients With Stage IV Melanoma

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Lentigo Maligna Melanoma | Mucosal Melanoma | Acral Lentiginous Melanoma | Cutaneous Nodular Melanoma | Low-CSD Melanoma

United States
Organon and Co

Completed

An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Solid Tumors | Leukemia, Lymphocytic, Chronic. B-Cell
M.D. Anderson Cancer Center
Schering-Plough

Withdrawn

SCH-900105 in Recurrent Glioblastoma

Glioblastoma
Merck Sharp & Dohme LLC

Withdrawn

Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)

Asthma
ALK-Abelló A/S

Completed

A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)

Conjunctivitis | Rhinitis Allergic
Merck Sharp & Dohme LLC

Completed

Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) (GO-MORE)

Arthritis, Rheumatoid
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)

Obesity | Overweight | Body Weight
Merck Sharp & Dohme LLC

Completed

A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)

Parkinson Disease
Merck Sharp & Dohme LLC

Completed

Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)

Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC

Completed

Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)

HIV Infections | Acquired Immunodeficiency Syndrome
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Schering-Plough

Completed

SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy

HIV Infections | Meningitis, Cryptococcal

United States

3

Subscribe